MedTrace Logo

Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

NCT06463717 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 210

Last updated 2024-06-24

No results posted yet for this study

Summary

The goal of this observational study is to compare the efficacy and safety of autologous hematopoietic stem-cell transplantation (ASCT) versus non ASCT regimens in primary multiple myeloma patients achieved MRD negativity after induction.

The main question it aims to answer is:

In primary multiple myeloma patients who achieved MRD negativity after induction, non ASCT regimens are not inferior to ASCT or not? Participants will receive ASCT or non ASCT regimen according to their own choice.

Researchers will compare ASCT and non ASCT group see if any significant difference in efficacy and safety.

Conditions

Interventions

DRUG

Transplant, Autologous

High-dose melphalan followed by autologous stem cell transplantation

DRUG

Chemotherapy drug

Regimen such as Bortezomib plus Lenalidomide plus Dexamethasone

Sponsors & Collaborators

  • First Affiliated Hospital of Wenzhou Medical University

    collaborator OTHER

  • The Affiliated Hospital of Medical College, Ningbo University

    collaborator OTHER

  • Dongyang People's Hospital

    collaborator OTHER

  • First Affiliated Hospital of Zhejiang University

    lead OTHER

Principal Investigators

  • Haitao Meng · Zhejiang University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2028-11-30
Completion
2028-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06463717 on ClinicalTrials.gov